N-Acetyl Epitalon Amidate
Also known as: NAEA · Ac-Ala-Glu-Asp-Gly-NH2 · N-Acetyl Epitalon
A chemically protected analogue of Epitalon with N-terminal acetylation and C-terminal amidation — same pineal-directed pharmacology as parent Epitalon with extended half-life, mirroring the NA-Semax and NA-Selank pattern.
N-Acetyl Epitalon Amidate (NAEA) is a chemically protected analogue of Epitalon with extended half-life; same pineal-directed pharmacology with fewer daily doses.
Evidence tier: C — preclinical / mechanistic evidence only
- Category
- Neuroprotection
- Half-life
- Substantially extended relative to parent Epitalon
Section 1
Overview
N-Acetyl Epitalon Amidate (NAEA) stands in the same architectural relationship to Epitalon as N-Acetyl Semax Amidate does to Semax and N-Acetyl Selank Amidate does to Selank. The parent Epitalon tetrapeptide (Ala-Glu-Asp-Gly) is chemically protected at both termini — N-terminal acetylation blocks aminopeptidase attack and C-terminal amidation blocks carboxypeptidase attack — producing an analogue with substantially extended pharmacokinetics but identical receptor pharmacology.
The compound retains Epitalon's positioning within the Khavinson bioregulator framework: pineal-directed transcriptional modulation, telomerase induction, melatonin-rhythm restoration, and the broader gerontoprotective effect profile. The practical advantage is the same as for the other N-acetyl amidate analogues on this site — fewer daily doses for equivalent pharmacodynamic effect, and a more sustained rather than pulsatile exposure profile.
The evidence base for NAEA specifically is thinner than for parent Epitalon, which itself has a thinner Western evidence base than most other peptides on this reference. Research-context selection between parent Epitalon and NAEA follows the same logic as for the Semax and Selank analogues: parent for the deeper evidence base, analogue for the better pharmacokinetics.
Section 2
Discovery & History
- Developed as the terminally-protected analogue of parent Epitalon, applying the same N-acetylation + C-amidation stabilisation strategy that had previously been used on Semax and Selank in the Russian research programme.
- Extends the Khavinson short-peptide programme by adding a protected-analogue variant with improved pharmacokinetic characteristics.
- The N-acetyl amidate variant follows the same architectural pattern established for the Semax and Selank protected analogues, providing an analogue-family design template.
- Studied in Russian preclinical research alongside parent Epitalon in comparative pharmacokinetic and pharmacodynamic characterisations.
- Remains a research chemical in all jurisdictions; no clinical evaluation has been conducted specific to the analogue.
Section 3
Mechanism of Action
- 1Pharmacologically identical mechanism profile to parent Epitalon — proposed direct DNA-binding transcriptional modulation of pineal-relevant gene promoters, telomerase induction in cultured cells, and pineal-directed circadian effects operating through the same molecular route as parent-compound Epitalon.
- 2Extended half-life through N-terminal acetylation and C-terminal amidation, blocking the two principal proteolytic clearance pathways — aminopeptidase-driven attack on the free α-amine and carboxypeptidase-driven attack on the free carboxylate — the same protection strategy applied to the Semax and Selank analogues.
- 3Greater bioavailability per administered dose and longer pharmacodynamic action relative to parent Epitalon, producing sustained rather than pulsatile receptor engagement across the inter-dose interval and thereby a smoother pharmacokinetic profile with lower peak-trough variability.
- 4The telomerase-induction magnitude at any given dose is reported to be equivalent or moderately greater than parent Epitalon, with the extended-exposure profile producing sustained rather than peak-and-clear effects on cellular replicative-lifespan endpoints in in-vitro fibroblast preparations.
- 5Antioxidant and neuroendocrine-modulating effects preserved from the parent-compound pharmacology — upregulation of endogenous antioxidant enzyme expression (SOD, catalase, glutathione peroxidase) and modulation of gonadotropin and cortisol axes in aged research contexts.
- 6The pineal-directed transcriptional mechanism operates identically to parent Epitalon; the analogue changes only pharmacokinetics without altering the receptor pharmacology or the downstream biochemistry.
- 7Melatonin-rhythm restoration in age-blunted circadian baselines — the phenotypic biomarker of the pineal-targeting mechanism, preserved from the parent-compound activity profile and enhanced by the extended-exposure characteristic of the analogue.
- 8Anti-apoptotic and cellular-preservation effects in stressed neuronal and non-neuronal cell preparations, consistent with the broader Khavinson-family antioxidant and stress-resilience mechanism.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Extended duration of action versus parent Epitalon — fewer daily doses required to maintain equivalent pharmacodynamic effect, translating to better adherence in long research protocols and lower variability from missed doses.
- 2Same telomerase-induction, melatonin-rhythm-restoration, and gerontoprotective profile as parent Epitalon; the analogue's pharmacology is qualitatively identical, only quantitatively (pharmacokinetically) different.
- 3Improved per-dose potency in some research endpoints where the pharmacokinetic extension multiplies AUC (area under the exposure curve) per administered dose.
- 4Compatible with the standard Khavinson bioregulator stacking framework (Pinealon, Vesugen, Cortagen, and other family members) — the analogue integrates into the same protocol conventions as parent Epitalon.
- 5Suitable for less frequent parenteral or intranasal dosing in research protocols, reducing administration frequency without loss of pharmacodynamic effect.
- 6Smoother exposure profile with less peak-trough variability than parent Epitalon — a pharmacokinetic advantage for research endpoints that benefit from sustained rather than pulsatile exposure.
- 7Preserved anti-apoptotic and antioxidant effects across cellular and animal-model research contexts.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Intranasal / parenteral (research) | Microgram-range doses following adapted Khavinson protocol conventions | 1× daily versus 2× for parent Epitalon at comparable doses | 10-day cyclical courses following the standard Khavinson pattern |
Note: Analogue-specific dosing conventions are less well-established than parent-Epitalon protocols; the practical advantage is the reduced dosing frequency.
Section 6
Administration Routes
- Intranasal administration — a common route for Khavinson short-peptide analogues, exploiting nose-to-brain delivery for the CNS-directed effects.
- Subcutaneous administration in research contexts where systemic exposure and reproducible pharmacokinetic characterisation is prioritised.
- Intramuscular administration in some Russian clinical protocols where injection-volume constraints permit.
- Oral administration is not viable — despite terminal protection, internal peptide bonds remain susceptible to gastrointestinal proteolysis and undergo near-complete first-pass metabolism.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in animal research at studied doses — consistent with the Khavinson-family unusually clean acute-tolerability profile characterised across the whole short-peptide programme.
- · Mild local irritation possible with intranasal administration; typically transient and self-limiting within the first 2–3 doses of a course.
- · Occasional mild transient effects during initial dosing, generally resolving with continued administration as the tolerance-adaptation curve completes.
- · The parent Epitalon safety database provides partial extrapolation coverage for the analogue's expected safety profile at studied doses.
Rare / theoretical
- · Long-term safety data is limited — the analogue-specific safety database is very sparse and chronic-use safety beyond several months has not been formally characterised.
- · The direct DNA-binding mechanism (extrapolated from parent Epitalon) remains debated in Western pharmacology and would require independent replication to inform a full regulatory-scale safety evaluation.
- · Telomerase-induction concerns extrapolated from parent-compound theoretical considerations — the same theoretical tumour-risk framing that applies to parent Epitalon carries across to the analogue.
- · Theoretical interaction with epigenetic-modifier drugs given the proposed transcriptional-modulation mechanism.
Contraindications
- · Not licensed for human use in the UK.
- · Pregnancy and lactation — no controlled human data.
- · Active or historic malignancy — theoretical contraindication via the telomerase-induction mechanism (extrapolated from parent Epitalon).
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine in the UK. Research chemical only.
European Union
Not approved by the EMA.
Section 9
Clinical Studies Summary
Pharmacokinetic comparison of Epitalon and N-acetyl analogue
Comparative pharmacokinetic characterisation of Epitalon and NAEA at matched doses in a rodent model, demonstrating substantially extended plasma half-life (approximately 3-fold) and prolonged tissue exposure for the acetylated/amidated analogue versus parent Epitalon. Establishes the pharmacokinetic scaffold that motivates the analogue's positioning as an extended-duration Epitalon variant and provides the biochemistry-level demonstration of the terminal-protection mechanism.
NAEA telomerase-induction and cellular ageing effects
Cellular research in human fibroblast preparations demonstrating preserved or moderately enhanced telomerase-induction effect of NAEA versus parent Epitalon at matched doses, with the extended exposure profile producing more sustained rather than peak-and-clear effects on cellular replicative lifespan endpoints. Extends the parent-Epitalon telomerase-induction evidence base into the analogue-specific research context.
NAEA in Khavinson bioregulator framework
Positioning research characterising NAEA within the broader Khavinson short-peptide programme, extending the parent-analogue pattern established for Semax and Selank into the Epitalon pineal-directed research pathway and providing the theoretical framework for the analogue's positioning as a Khavinson-family-conforming extended-duration Epitalon variant.
NAEA melatonin-rhythm effects in aged rodent models
Behavioural and endocrinology characterisation of NAEA's melatonin-rhythm-restoration effects in aged rodent cohorts, demonstrating preservation of parent-Epitalon's phenotypic circadian-restoration effects with an extended time-course of pharmacodynamic action following administration. Confirms qualitative equivalence to the parent compound with quantitative pharmacokinetic extension.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing N-Acetyl Epitalon Amidate for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain N-Acetyl Epitalon Amidate from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.